ELOVL2 gene polymorphisms are associated with increases in plasma eicosapentaenoic and docosahexaenoic acid proportions after fish oil supplement

Table 5 Proportions of plasma EPA and DHA after treatment, stratified by ELOVL2 rs953413 genotype

Treatment	n (GG/GA + AA)^a	EPA			DHA
Treatment	n (GG/GA + AA)^a	GG	GA + AA	P*	GG	GA + AA	P*
Placebo	21/45	1.00 (0.86,1.14)	0.96 (0.87,1.06)	0.934	2.22 (2.07,2.37)	2.22 (2.12,2.32)	0.544
0.45 g/day	15/54	2.10 (1.70,2.51)	1.77 (1.55,1.98)	0.199	3.00 (2.75,3.25)	2.85 (2.72,2.98)	0.189
0.90 g/day	23/52	2.55 (2.27,2.83)	2.27 (2.09,2.46)	0.050	3.35 (3.15,3.56)	3.34 (3.21,3.48)	0.671
1.80 g/day	20/50	3.23 (2.75,3.72)	4.19 (3.88,4.50)	0.004	3.89 (3.65,4.13)	4.21 (4.06,4.36)	0.017

Data show mean (95 % CI) follow-up values for EPA and DHA as a percentage of total fatty acids, adjusted for baseline. Subjects received supplements of EPA and DHA (1.51:1) at the daily doses shown for 6 month
EPA eicosapentaenoic acid; DHA docosahexaenoic acid
* Significance of genotype association with proportions of fatty acids with respect to SNP genotype based on a dominant model was tested by multivariate ANOVA. Interaction between genotype andtreatment was a significant determinant of EPA (P < 0.0001) and DHA (P = 0.032). All P-values were adjusted for baseline values, BMI, age, gender and ethnicity
^a n = number of subjects in genotype groups GG and GA + AA

ISSN: 1865-3499